Browse more cannabis research, findings, methods, and limitations.
Analysis of the ABCD cohort found that prenatal cannabis exposure was associated with mental health burden that persisted into early adolescence, suggesting the link is not limited to early childhood.
A rat study found high-THC cannabis smoke impaired working memory but not attention, while high-CBD smoke caused no cognitive deficits.
A review details how DNA methylation, histone changes, and RNA networks regulate cannabinoid receptor expression in health and disease.
Boosting anandamide in adolescent rats reversed schizophrenia-like cognitive and social deficits through distinct CB1 and CB2 receptor pathways.
A survey of 505 Australian GPs found growing acceptance of medicinal cannabis since 2017, but most felt they lacked adequate knowledge to prescribe confidently.
CBD disrupted fear memory reconsolidation in rats through CB1 receptors in the anterior cingulate and prelimbic cortex, not the infralimbic cortex.
Cannabis-related ER visits among Ontario youth rose 4.8-fold from 2003 to 2017, with higher severity and hospital admission rates than non-cannabis visits.
A global survey of 107,272 people found cannabis was more commonly smoked indoors than tobacco, with 78.8% of cannabis-only users smoking at home vs. 67.9% of tobacco-only users.
A stabilized CBDA derivative reduced weight and improved metabolic markers in both diet-induced and genetically obese mouse models.
A review finds CBD has evidence for reducing anxiety, but THC effects are mixed. Despite limited evidence, anxiety cannabis prescriptions are rising rapidly in Australia.
An open-label trial of 31 young people with treatment-resistant anxiety found 12 weeks of add-on CBD (up to 800 mg/day) reduced anxiety severity by 42.6%.
A controlled study found vaporized CBD reached 8-12x higher blood levels than oral CBD at the same dose, and pure CBD did not produce THC in the body.
First reported case of a 17-year-old developing superior mesenteric artery syndrome (bowel obstruction) from rapid weight loss caused by cannabinoid hyperemesis syndrome.
A novel oral cannabis delivery system (Solutech) produced faster, higher blood levels of THC and CBD than standard oil, and cannabis use history significantly shaped pharmacokinetic profiles.
A meta-analysis of six long-term studies found cannabis produced modest pain reduction (1.75 points on a 0-10 scale) for chronic pain, but evidence quality was very low and nearly half of patients stopped treatment.
A naturalistic study found flower and edible cannabis users reached similar levels of intoxication and memory impairment despite flower users having higher blood THC levels.
A meta-analysis of 152 RCTs found CBD has high-grade evidence for epilepsy, while dronabinol and nabiximols show moderate evidence for pain, spasticity, and other conditions.
In a 3-year follow-up of first-episode schizophrenia patients, 93.2% of those who relapsed used cannabis, compared to 56.7% of those who stayed in remission.
An expert panel rated state monopoly as the most effective cannabis policy for reducing youth use, excessive use, and impaired driving, while noting almost no direct evidence exists for most policies.
Testing cannabis compounds in human immune cells found THC had the broadest anti-inflammatory activity, while popular terpenes like limonene had no measurable immune effects.
A survey of 1,087 chronic pain patients found those using both inhaled and oral cannabis reported greater health improvements and more medication substitutions than single-route users.
A survey of 878 fibromyalgia patients found typical CBD doses under 50 mg/day, with no relationship between dose and reported benefit, and most patients guided by personal research rather than doctors.
Substance users and addiction experts agreed that cannabis is less harmful than alcohol or benzodiazepines, but users rated cannabis benefits significantly higher than experts did.
A CBD-and-terpene-enriched cannabis extract reduced brain immune cell inflammation more effectively than pure CBD alone, through multiple molecular pathways.
A review warns that cannabis exposure in autistic individuals may increase psychosis risk through epigenetic effects on shared genetic pathways, with potential intergenerational consequences.
The synthetic mirror image of CBD, (+)-CBD, was 10 times more potent at blocking CB1 signaling than natural (-)-CBD and activated an entirely different receptor system.
A review finds fibromyalgia patients have altered endocannabinoid systems and that cannabinoid treatments show promise, but methodological gaps prevent clinical recommendations.
A review of Canada's cannabis legalization finds mixed public health impacts: use increased in some groups, smoking declined, hospitalizations showed mixed results, and impaired driving prevalence was stable.
A one-year study of 339 young adult cannabis users found childhood trauma led to problematic use primarily through using cannabis to cope with distress, while sleep-motivated use was not associated with problems.
Boosting the endocannabinoid 2-AG in a brain defense region reduced fear and anxiety in rats through both CB1 and CB2 receptors.
A survey across three U.S. states found earlier cannabis use onset, male sex, and living in a legal state were linked to more cannabis-impaired driving and more positive safety perceptions.
A review finds standard antiemetics often fail for CHS, while haloperidol, benzodiazepines, and capsaicin cream are the most effective treatments. Only cannabis cessation resolves the condition completely.
A Spanish ER study found CHS at 4.4 per 10,000 visits, with 50% recurrence and topical capsaicin resolving vomiting in about 18 minutes.
A driving study found self-reported cannabis effects predicted driving performance beyond THC dose, but which feelings mattered varied between studies, with "stoned" being the most consistent.
The deadly synthetic cannabinoid 5F-MDMB-PINACA produces metabolites that remain active at CB1 receptors with atypical pharmacology, potentially explaining its severe toxicity.
A study of 8,008 pregnant women found cannabis use altered placental blood vessel development markers and was associated with higher risk of pregnancy complications.
Children exposed to prenatal cannabis had higher BMI and body fat at age 10, but similar associations with paternal use suggest family lifestyle factors rather than direct fetal effects.
Cannabis-induced psychosis ER visits doubled from 2015-2019 in Ontario and Alberta, but statistical analysis found no significant increase attributable to Canada's 2018 legalization.
A 20-month study of 59 children with drug-resistant epilepsy found CBD-enriched cannabis reduced seizures by 71% on average, with 12% achieving seizure freedom.
A study of 926 boys identified six substance use trajectories through adolescence, with impulsive sensation-seekers at highest risk for early-onset polysubstance use including marijuana.
Analysis of 328 cannabis marketing violations in Washington State found violations common online and near stores, with community members identifying many targeting minors.
Most systematic reviews on cannabis use disorder treatments had authors with conflicts of interest (78%), but no significant relationship was found between COIs and biased results.
A systematic review of 22 cohort studies found no consensus on whether cannabis causes suicidal behavior, though heavier or earlier use may increase risk.
A French national survey found 10% of adults use CBD, with users tending to be younger, in poorer health, and viewing CBD as harmless.
Marijuana improved spatial learning in female rats, but combining it with estrogen in older rats produced negative cognitive effects through the GPR30 receptor.
Cannabis vaporizers reduce respiratory toxins and symptoms compared to smoking but are not risk-free, especially for new users who face cognitive impairment and dependence risks.
A national survey found 29% of flavored cigar smokers would switch to cannabis if flavored cigars were banned, with racial/ethnic minorities more likely to make the switch.
A genetic analysis found cannabis use disorder was independently linked to higher risk of atrial fibrillation, heart failure, pulmonary embolism, and stroke, beyond traditional cardiovascular risk factors.
A review of 26 studies found healthcare professionals see medicinal cannabis as a viable pain option but consistently feel underprepared to prescribe it, citing lack of education and clinical guidelines.
A survey of 70 psychosis patients found 86% willing to try CBD treatment, with most expecting symptom improvement and fewer side effects than antipsychotics.